Genzyme deal.

The article reports on the license and collaboration agreement of the U.S. Genzyme and Isis Pharmaceuticals in California. It states that the agreement is for Genzyme's mipomersen, a lipid-lowering drug. In addition, mipomersen cuts down the production rate of apoB-100 protein that is vital to transferring bad cholesterol. According to the author, Isis Pharmaceuticals receives $175 million for the license fee and another $50 million for its growth. Also, other expenses along the process are to be divided evenly.